Abstract

BackgroundThe clinical target volume (CTV) for postoperative radiotherapy for thoracic esophageal squamous cell carcinoma (TESCC) needs to be defined. The study aim was to map metastatic lymph nodes (LNMs) in a computed tomography (CT)-based atlas and delineate the postoperative radiotherapy target area.MethodsSixty-nine TESCC patients with first recurrent regional LNMs after esophagectomy were included. The LNM epicenters were registered onto corresponding anatomic axial CT images of a standard patient in the treatment position, with reference to the surrounding vascular and bony structures. The LNM sites were based on lymph node map of esophageal cancer, AJCC 8th. The lymph metastasis risk for different segments of thoracic esophagus was assessed.ResultsOne hundred and seventy-nine LNMs were mapped onto standard axial CT images. The upper-middle mediastinum region (station 1 to 8 M) contained 97% of metastases in the upper segment of thoracic esophagus, 90% in the middle segment, and 66% in the lower one. Advanced pathological stage (≥IIIB) might be a predictive factor for upper abdominal region (UAR) relapse in lower TESCC. Lower cervical para-tracheal LNMs were within a 4.3-cm bilaterally expanded area from the midline of the body and a 2.2-cm expanded area from the anterior of vertebral body, from the superior border of the C7, to the inferior border of the first thoracic vertebra.ConclusionA modified target from the upper border of C7 to the lower border of caudal margin of the inferior pulmonary vein level could cover the high-risk area of TESCC underwent postoperative radiotherapy. UAR seems to be an elective irradiation target for lower TESCC at pathological IIIB stage and higher.

Highlights

  • The clinical target volume (CTV) for postoperative radiotherapy for thoracic esophageal squamous cell carcinoma (TESCC) needs to be defined

  • According to the latest Metastatic lymph nodes (LNMs) maps of esophageal cancer and the results in this study, we found that the upper-middle mediastinum region (UMMR) had the highest risk of recurrence for upper and middle TESCC

  • In our computed tomography (CT)-based LNM map, we found that the UMMR had high metastasis risk for all segments TESCC

Read more

Summary

Introduction

The clinical target volume (CTV) for postoperative radiotherapy for thoracic esophageal squamous cell carcinoma (TESCC) needs to be defined. Based on the landmark CROSS study, preoperative chemoradiation followed by surgery is the preferred treatment strategy for resectable stage II and III thoracic esophageal carcinoma [3]. A recent study from china confirmed the potential value of preoperative chemoradiation for thoracic esophageal squamous cell carcinoma (TESCC), though a longer follow-up result was still needed [4]. A large population-based study found that esophagectomy in the real-world was not a rare initial treatment for thoracic esophageal carcinoma. A total of 4893 patients were chosen to receive initial esophagectomy (including adenocarcinoma and squamous cell carcinoma) between 2008 and 2011 the United States [5]. Postoperative radiotherapy seems to be an important adjuvant therapy for TESCC

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call